FUCASO BCMA CAR-T

FUCASO BCMA CAR-T Therapy

FUCASO, developed by Nanjing IASO Biotechnology, is a groundbreaking CAR-T therapy specifically designed to target B-cell maturation antigen (BCMA). This therapy stands out for its unparalleled clinical efficacy and safety profile, providing a new hope for patients with relapsed or refractory multiple myeloma (r/rMM). Approved by the National Medical Products Administration (NMPA) on June 30, 2023, FUCASO has already demonstrated significant success in clinical applications.

Advantages of FUCASO BCMA CAR-T Therapy

Exceptional Efficacy: FUCASO demonstrates an outstanding Overall Response Rate (ORR) of 98.9%, with a Complete Response (CR) rate reaching 82.4%, far surpassing the outcomes of existing treatment options.

Sustained Disease Control: Patients treated with FUCASO exhibit a durable remission, with a 12-month Progression-Free Survival (PFS) rate of 85.5%, signifying prolonged periods without disease progression and enhanced life quality.
Superior Safety Profile: The therapy shows minimal severe side effects, with grade 3 or higher Cytokine Release Syndrome (CRS) occurring in only 1% of cases and no reported instances of severe Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), making it a safer alternative to conventional CAR-T treatments.
Cost-Effectiveness: Compared to similar therapies available in Western countries, FUCASO is more affordable, presenting wider accessibility to patients globally.
Global Treatment Network: IASO BIO has established a robust network of treatment centers throughout China, offering comprehensive services from initial consultation to post-therapy care, welcoming patients from around the world.

Treatment Process

Patient Evaluation: The medical team conducts a thorough assessment of the patient’s condition to determine suitability for FUCASO treatment.
T Cell Collection: Immune cells (T cells) are collected from the patient’s blood via a process called leukapheresis.
CAR-T Cell Engineering: These T cells are then genetically modified in specialized laboratories to express the chimeric antigen receptor (CAR) that specifically targets BCMA on malignant plasma cells.
Cell Expansion: The engineered CAR-T cells are expanded in number to ensure sufficient quantities for therapeutic effect.
CAR-T Cell Infusion: The modified CAR-T cells are infused back into the patient’s bloodstream, where they seek out and destroy BCMA-expressing cancer cells.